ICON9 An international phase III randomised study to evaluate the efficacy of maintenance cediranib and olaparib combination therapy or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
Funding or Partner Organisation: Cancer Research UK
Cancer Research UK
Start year: 2018
FOR Codes: Health Economics, Health Policy Economic Outcomes